Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 19/20 | 0.54 |
| ▸ | JAK1 | P23458 | 17/20 | 0.54 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2104803 | 0.81 | JAK3 (0.58) | JAK3JAK1NUDT1 | |
| SCHEMBL22954413 | 0.80 | JAK3 (0.64) | JAK3JAK1NUDT1 | |
| SCHEMBL2103898 | 0.79 | JAK3 (0.56) | JAK3JAK1NUDT1 | |
| SCHEMBL2105342 | 0.79 | JAK3 (0.56) | JAK3JAK1NUDT1 | |
| SCHEMBL13636626 | 0.77 | JAK3 (0.37) | JAK3JAK1NUDT1 | |
| SCHEMBL2104887 | 0.76 | JAK2 (0.54) | JAK3JAK1 | |
| SCHEMBL29477133 | 0.74 | NUDT1 (0.65) | JAK3JAK1NUDT1 | |
| SCHEMBL20990227 | 0.74 | NUDT1 (0.65) | JAK3JAK1NUDT1 | |
| SCHEMBL566667 | 0.74 | NUDT1 (0.65) | JAK3JAK1NUDT1 | |
| SCHEMBL22954329 | 0.73 | JAK3 (0.85) | JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284637-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284637-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | JAK3 1/4885JAK1 2/4885NUDT1 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.